![](https://www.businessmarketinsights.com/assets/img/reports-icon.png)
Marktprognose für virusähnliche Partikel im asiatisch-pazifischen Raum bis 2028 – Auswirkungen von COVID-19 und regionale Analyse nach Produkttyp (Hepatitis, Krebs/HPV und Gaucher-Krankheit), Quelle (Hefe, Insektenzellen, Pflanze und andere) und Anwendung (Impfstoffe). und Therapeutika)
Der Markt für virusähnliche Partikel im asiatisch-pazifischen Raum wird voraussichtlich von 1.018,83 Millionen US-Dollar im Jahr 2021 auf 1.769,02 Millionen US-Dollar wachsen Millionen bis 2028; es wird von 2021 bis 2028 ein durchschnittliches Wachstum von 8,2 % erwartet.
Verschiedene Akteure des Gesundheitsmarktes und Forschungsorganisationen sind aktiv an Produktinnovationen und -entwicklungen beteiligt. Die Verwendung virusähnlicher Partikel ist ein neuer Ansatz in der Biopharmazeutikaindustrie. Da virusähnlichen Partikeln der virale Inhalt fehlt, sind sie einfacher zu handhaben als die eigentlichen viralen Bestandteile. Die VLPs können zur Unterstützung der Arzneimittelabgabe, Bildgebung, Immuntherapie und Theragnostik eingesetzt werden. Laut einer im Juni 2020 im NCBI veröffentlichten Studie kann VLP beispielsweise in Form von Nanopartikeln in Anwendungen wie Photothermietherapie, PET- und CT-Bildgebung, MRT-Kontrastmittelträgern, optischer Bildgebung sowie Impfstoffen gegen Entzündungs- und Autoimmunerkrankungen eingesetzt werden. Krebsimmuntherapie und niedermolekulare Arzneimittelabgabe (in der Krebstherapie). Daher wird erwartet, dass solche potenziellen Anwendungen von VLPs den Marktteilnehmern im Prognosezeitraum Wachstumschancen bieten.
Laut dem Bericht des Internationalen Währungsfonds (IWF). Es wurde erwartet, dass das Wachstum im asiatisch-pazifischen Raum im Jahr 2020 bei null Prozent stagnieren würde. Dies war die schlechteste Wachstumsleistung seit fast 60 Jahren, einschließlich der globalen Finanzkrise (4,7 %) und der asiatischen Finanzkrise (1,3 %). Die Abwärtskorrekturen waren erheblich und reichten von 3,5 % im Falle Koreas, schienen jedoch mit der langsamen Ausbreitung des Coronavirus zurechtzukommen, da längere Produktionsstillstände auf ein Minimum reduziert wurden und in Australien, Neuseeland und Thailand 9 % ausmachten. Diese Länder waren aufgrund der weltweiten Schließung des Tourismus und im Falle Australiens aufgrund niedrigerer Rohstoffpreise stark betroffen. Der asiatisch-pazifische Raum, in dem derzeit COVID-19-Impfstoffe entwickelt werden, umfasst Südkorea, China, Japan, Thailand und Vietnam. Davon verfügt China über 15 Impfstoffe, Indien und Südkorea über drei Impfstoffe, Japan über zwei Impfstoffe und Thailand und Vietnam über einen Impfstoff. Zu diesen Impfstoffen zählen zehn inaktivierte Impfstoffe, sechs Impfstoffe gegen Proteinuntereinheiten, sieben virale Vektorimpfstoffe und sechs Nukleinsäureimpfstoffe. Darüber hinaus hat die Förderung eines sicheren, gerechten und wirksamen Impfstoffs im asiatisch-pazifischen Raum höchste Priorität. Laut dem Bericht der Asiatischen Entwicklungsbank hat die Asiatische Entwicklungsbank (ADB) im Dezember 2020 eine 9-Milliarden-US-Dollar-Impfstoffinitiative mit der Asia Pacific Vaccine Access Facility (APVAX) gestartet, die dem Entwicklungsmitglied schnelle und gerechte Unterstützung bieten wird Länder (DMCs) zur Beschaffung und Bereitstellung wirksamer und sicherer COVID-19-Impfstoffe. Durch Impfungen kann die Kette der Virusübertragung unterbrochen, Leben gerettet und die negativen Auswirkungen der Pandemie abgemildert werden.
Mit dem Neuen Mithilfe von Funktionen und Technologien können Anbieter neue Kunden gewinnen und ihre Präsenz in aufstrebenden Märkten ausbauen. Dieser Faktor dürfte den Markt für virusähnliche Partikel im asiatisch-pazifischen Raum antreiben. Es wird erwartet, dass der Markt für virusähnliche Partikel im asiatisch-pazifischen Raum im Prognosezeitraum mit einer guten jährlichen Wachstumsrate wachsen wird.
Umsatz und Prognose auf dem Markt für virusähnliche Partikel im asiatisch-pazifischen Raum bis 2028 (Mio. US-Dollar)
Marktsegmentierung virusähnlicher Partikel im asiatisch-pazifischen Raum
Markt für virusähnliche Partikel im asiatisch-pazifischen Raum – Nach Produkttyp
- Hepatitis
- Krebs/HPV
- Gaucher-Krankheit
Markt für virusähnliche Partikel im asiatisch-pazifischen Raum – Nach Quelle
- Hefe
- Insektenzelle
- Pflanze
- Andere
Markt für virusähnliche Partikel im asiatisch-pazifischen Raum – Durch Anwendung
- Impfstoffe
- Therapeutika
Markt für virusähnliche Partikel im asiatisch-pazifischen Raum – Nach Land
- China
- Japan
- Indien
- Australien
- Südkorea
- Restlicher Asien-Pazifik-Markt für virusähnliche Partikel im asiatisch-pazifischen Raum – Erwähnte Unternehmen
- Merck & Co., Inc ; &n bsp ;
- GlaxoSmithKline plc.
- Pfizer Inc.  ; &n bsp ;   ;
- Sanofi   ;   ;
- < span>Serum Institute of India Pvt. Ltd.
- BHARAT BIOTECH   ; &n bsp ;
- LG Chem   ;   ; span>
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Virus-like Particles Market – By Product Type
1.3.2 Asia Pacific Virus-like Particles Market – By Source
1.3.3 Asia Pacific Virus-like Particles Market – By Application
1.3.4 Asia Pacific Virus-like Particles Market – By Country
2. Asia Pacific Virus-like Particles Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Virus-like Particles Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Experts Opinion
5. Asia Pacific Virus-like Particles Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Surging Prevalence of Infectious Viral Diseases
5.1.2 Increasing Role of Virus-Like Particles in Therapeutic Developments and Studies
5.2 Market Restraints
5.2.1 Reach of Alternative Technologies for Viral Vaccine Production
5.3 Market Opportunities
5.3.1 Growing Potential Applications in Therapeutics and Diagnostics
5.4 Future Trends
5.4.1 Steady Demand for Innovative and Effective Products
5.5 Impact Analysis
6. Asia Pacific Virus-like Particles Market Analysis
6.1 Asia Pacific Virus-like Particles Market Revenue Forecast and Analysis
7. Asia Pacific Virus-like Particles Market Analysis – by Product Type
7.1 Overview
7.2 Asia Pacific Virus-like Particles Market, by Product Type, 2021 & 2028 (%)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
7.4 Cancer/ Human Papillomavirus (HPV)
7.4.1 Overview
7.4.2 Cancer/HPV: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
7.5 Gaucher Disease
7.5.1 Overview
7.5.2 Gaucher Disease: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
8. Asia Pacific Virus-like Particles Market Analysis – By Source
8.1 Overview
8.2 Asia Pacific Virus-like Particles Market Share, by Source, 2021 & 2028 (%)
8.3 Yeast
8.3.1 Overview
8.3.2 Yeast: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
8.4 Plant
8.4.1 Overview
8.4.2 Plant: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
8.5 Insect Cell
8.5.1 Overview
8.5.2 Insect Cell: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
9. Asia Pacific Virus-like Particles Market Analysis – By Application
9.1 Overview
9.2 Asia Pacific Virus-like Particles Market Share, by Application, 2021 & 2028 (%)
9.3 Vaccines
9.3.1 Overview
9.3.2 Vaccine: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
9.4 Therapeutics
9.4.1 Overview
9.4.2 Therapeutics: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
10. Asia Pacific Virus-like Particles Market – Country Analysis
10.1 Overview
10.1.1 Asia Pacific: Virus-like Particles Market Revenue and Forecast to 2028, by Country (%)
10.1.1.1 Japan: Virus-Like Particles Market Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 Japan: Virus-Like Particles Market Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.3 Japan: Virus-Like Particles Market Revenue and Forecasts to 2028, by Product Type (US$ Million)
10.1.1.1.4 Japan: Virus-Like Particles Market Revenue and Forecasts to 2028, by Source (US$ Million)
10.1.1.1.5 Japan Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.2 China: Virus-Like Particles Market Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 China: Virus-Like Particles Market Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.3 China Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.4 China: Virus-Like Particles Market Revenue and Forecasts to 2028, by Source (US$ Million)
10.1.1.2.5 China Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.3 India Virus-Like Particles Market Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 India: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.3 India Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.4 India Virus-like Particles Market, by Source - Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.5 India Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.4 South Korea: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 South Korea: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.3 South Korea Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.4 South Korea Virus-like Particles Market, by Source - Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.5 South Korea Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.5 Australia: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 Australia: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.3 Australia Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.4 Australia Virus-like Particles Market, by Source - Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.5 Australia Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.6 Rest of Asia Pacific: Virus-Like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Asia Pacific: Virus-Like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.3 Rest of Asia Pacific Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.4 Rest of Asia Pacific Virus-like Particles Market, by Source - Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.5 Rest of Asia Pacific Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
11. Impact Of COVID-19 Pandemic on Asia Pacific Virus-like Particles Market
11.1 Impact Assessment of COVID-19 Pandemic
12. Asia Pacific Virus-like Particles Market–Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 Merck & Co., Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 GlaxoSmithKline plc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Pfizer Inc.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Sanofi
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Wantai BioPharm
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Serum Institute of India Pvt. Ltd.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 BHARAT BIOTECH
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 LG Chem
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific Virus-like Particles Market, Revenue and Forecast to 2028 (US$ Million)
Table 2. Japan: Virus-Like Particles Market Revenue and Forecasts to 2028, by Product Type (US$ Million)
Table 3. Japan: Virus-Like Particles Market Revenue and Forecasts to 2028, by Source (US$ Million)
Table 4. Japan Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 5. China Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 6. China: Virus-Like Particles Market Revenue and Forecasts to 2028, by Source (US$ Million)
Table 7. China Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 8. India Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 9. India Virus-like Particles Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 10. India Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 11. South Korea Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 12. South Korea Virus-like Particles Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 13. South Korea Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 14. Australia Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 15. Australia Virus-like Particles Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 16. Australia Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 17. Rest of Asia Pacific Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 18. Rest of Asia Pacific Virus-like Particles Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 19. Rest of Asia Pacific Virus-like Particles Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 20. Organic Developments Done by Companies
Table 21. Inorganic Developments Done by Companies
Table 22. Glossary of Terms: Virus-like Particles Market
LIST OF FIGURES
Figure 1. Asia Pacific Virus-like particles Market Segmentation
Figure 2. Asia Pacific Virus-like particles Market Segmentation, By Country
Figure 3. Asia Pacific Virus-like Particles Market Overview
Figure 4. Hepatitis Held the Largest Share of the Product Type Segment in Asia Pacific Virus-like particles Market
Figure 5. India to Show Significant Growth during Forecast Period
Figure 6. Asia Pacific Virus-like Particles Market, Industry Landscape
Figure 7. Asia Pacific PEST Analysis
Figure 8. Asia Pacific Virus-like Particles Market: Impact Analysis of Drivers and Restraints
Figure 9. Asia Pacific Virus-like Particles Market– Revenue Forecast and Analysis to 2028
Figure 10. Asia Pacific Virus-like Particles Market, by Product Type, 2021 & 2028 (%)
Figure 11. Hepatitis: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
Figure 12. Cancer/HPV: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
Figure 13. Gaucher Disease: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
Figure 14. Asia Pacific Virus-like Particles Market Share, by Source, 2021 & 2028 (%)
Figure 15. Yeast: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 16. Plant: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 17. Insect Cell: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 18. Others: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Asia Pacific Virus-like Particles Market Share, by Application, 2021 & 2028 (%)
Figure 20. Vaccine: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Therapeutics: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Asia Pacific Virus-like Particles Market Overview, by Country (2021)
Figure 23. Asia Pacific: Virus-like Particles Market Revenue and Forecast to 2028, by Country (%)
Figure 24. Japan: Virus-Like Particles Market Revenue and Forecast to 2028 (US$ Million)
Figure 25. China: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
Figure 26. India: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
Figure 27. South Korea: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
Figure 28. Australia: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
Figure 29. Rest of Asia Pacific: Virus-Like Particles Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Sanofi
- Serum Institute of India Pvt. Ltd.
- BHARAT BIOTECH
- LG Chem
- Wantai BioPharm
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific virus-like particles market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific virus-like particles market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the virus-like particles market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution